Compare TG Therapeutics Inc (TGTX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TJX Companies Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 18.7× TG Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TJX Companies Inc for 97 Days on average.
| TGTX | TJX | |
|---|---|---|
Market Cap | $8.16B | $152.62B |
Volume | 1,735,121 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $168.41 |
52-Week Low | $26.94 | $122.84 |
Typical Hold Time | 16 Days | 97 Days |
Enterprise Value | $8.37B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
TJX trades at $138.75, down slightly by 0.04% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growing from $48.5B in 2022 to $56.4B in 2025, and net income margin expanding to 8.63%. Recent quarters have consistently beaten EPS expectations, and analysts project a consensus price target of $174.15, implying 28% upside. The stock is supported by robust cash flow from operations of $6.12B in 2025 and a healthy balance sheet with $5.34B in cash.
The outlook for TJX is positive, driven by earnings growth, market share gains in off-price retail, and Wall Street's strong buy consensus. Key risks include competitive pressures, consumer spending volatility, and elevated valuation multiples. The stock presents a compelling opportunity for growth-oriented investors, though near-term technical overbought conditions warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
